TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Maas, Ralph Ja, Hoogstad-van Evert, Janneke S, Van der Meer, Jolien Mr, Mekers, Vera, Rezaeifard, Somayeh, Korman, Alan J, de Jonge, Paul Kjd, Cany, Jeannette, Woestenenk, Rob, Schaap, Nicolaas Pm, Massuger, Leon F, Jansen, Joop H, Hobo, Willemijn, Dolstra, Harry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657585/
https://www.ncbi.nlm.nih.gov/pubmed/33224630
http://dx.doi.org/10.1080/2162402X.2020.1843247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657585/
https://www.ncbi.nlm.nih.gov/pubmed/33224630
http://dx.doi.org/10.1080/2162402X.2020.1843247

Ejemplares similares